Updated on 12 June 2012
Recently there is an upward trend for stem cell activity within Asia. This has resulted in the increased sales of high throughput screening devices. Consequently, the demand for storage of cord blood and stem cell in biobanks has increased. The private sector targets more on the cord and stem cell banking when compared to any other tumor or tissue repositories which are more public in nature.
Adoption of automation is slow but steady in Asia. This will also result in a slow down for the adoption of tools in other economies for example US, and Africa. The market has to develop in terms of operating private biobanks for profit. Additionally, legal and ethical issues need to be sorted out in order to enable the best use of biospecimens stored in public biobanks.
List of important biobanking projects/centers in Asia
|Singapore||NUS-NUH Tissue Repository, SingHealth Tissue Repository|
|Malaysia||UMCRI Tumour Tissue Bank, Cryocord Premiere stem cell bank|
|Japan||RIKSEN Bioresource center cell bank|
|China||Institutional Tissue Bank Fudan university, China cord blood corporation|
|Korea||National Biobank of Korea (NBK)|
|India||ICMR National Tumour Tissue Repository, TCS Life Sciences (The Chatterjee Group)|